BnR Summit 2025

Belt and Road Summit 2025- Deal-making

10 – 16 Sept 2025 | China (Hong Kong)

ProjectUpdated on 29 August 2025

Conjugated drug development platform

Hoi Yee Chow

COO at Serilink Biotechnology Company Limited

Hong Kong, China (Hong Kong)

About

Serilink is a company specializes in bioconjugation for conjugated drug development. We are a spin-off from chemistry department of HKU.

We are utilizing our in-house novel conjugation technology to develop various conjugated drug, with a focus on antibody-drug conjugate (ADC), peptide-drug conjugate (PDC) and radionuclide-drug conjugate (RDC).

We are seeking funding to support our pre-clinical studies for our PCC and also finding collaborators for co-development project.

Project Location

  • China (Hong Kong)

Project Format

  • Private Project

ESG (Environmental, Social, and Governance)

  • No

Project Stage

  • Project Planning

Main Project Sector

  • Technology

Technology

  • Bio-Tech
  • Health Technology
  • Medical Technology

Total Project Value

  • 5,000,001 to 7,500,000 USD

Investment Capital Required

  • 1,000,001 to 2,500,000 USD

Interested Format of Cooperation

  • Joint Venture
  • Open for Negotiation
  • R&D Cooperation

Preferred Financing Model

  • Open for negotiation

Previous Funding Stage

  • Seed & Pre-Series

Main Service(s) Required

  • Financial Services
  • Professional Services

Financial Services

  • Private Equity & Venture Capital

Professional Services

  • Business Valuation
  • Consultancy
  • IP Related

Attached files

Organisation

Serilink Biotechnology Company Limited

Hong Kong, China (Hong Kong)

Similar opportunities